Inovio Pharmaceuticals (INO) Net Equity Issued and Repurchased (2010 - 2026)

Inovio Pharmaceuticals has reported Net Equity Issued and Repurchased for 17 years, with the latest figure at $1.1 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased fell 1.64% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 96.61% YoY) and the FY2025 annual result came in at $1.1 million, down 96.95% from the prior year.
• Net Equity Issued and Repurchased rose to $1.1 million in Q1 2026 per INO's latest filing, from -$7.2 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $43.2 million in Q2 2022 and troughed at -$7.2 million in Q4 2025.
• A 5-year average of $8.4 million and a median of $3.8 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 977.12% in 2025, down 154.94% in 2025.
• Over 5 years, Net Equity Issued and Repurchased stood at $6.7 million in 2022, then tumbled by 72.43% to $1.8 million in 2023, then jumped by 611.62% to $13.1 million in 2024, then plunged by 154.94% to -$7.2 million in 2025, then jumped by 115.08% to $1.1 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $1.1 million, -$7.2 million, and $7.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.